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Abstract
Studying on subclonal evolution of cancer stem cells can help illustrate how the immune system 
recognizes tumor cells, leading to subclonal treatment by immune-based therapies. Here, we 
discuss that cancer subclones derived from the patient’s head and neck squamous cell carcinoma 
tumor stem cells can be used for the screening of personalized antitumor immunotherapy and 
chemotherapy, to maximize benefits and to minimize the adversary effects, toward personalized or 
precision medicine. We propose a “wait-and-watch” scheme for monitoring a lifetime cancer stem 
cell subclonal development evolved with local environments to cancer.
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INTRODUCTION
The US National Cancer Institute (NCI) and the National Human Genome Research Institute 
(NHGRI) created the Cancer Genome Atlas (TCGA) Project in 2006 with bulk tumor of 
cellular heterogeneity with one-time point [1]. However, it is essential to track down 
subclonal evolution of cancer stem cells (CSCs) evolving with treatment, such as 
Temodar®-driven mutations [2,3]. Indeed, Darwinian pressures arising from systemic 
therapy, result in the clonal selection of initially rare subclone variants within a tumor. Novel 
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technologies such as single cell circulating tumor cell sequencing would allow real-time 
monitoring of clonal heterogeneity, including Loss of heterozygosity (LOH) assays at 
genetic DNA level, at primary and metastatic sites, as well as for improved targeted early 
intervention, better care, prognosis, tumor subclonal recognition with immunotherapy [4]. 
This approach is of particular interest in highly lethal cancers like glioblastomas and 
colorectal adenocarcinomas, which express high intratumoral heterogeneity when a single 
signaling network is observed [5,6]. Therefore, advances in transcriptome analysis at single-
cell resolutions have become increasingly sought out tools to investigate causative signal 
pathways alterations in cancer, as they can specifically address the shortcomings of studying 
bulk lysates for heterogeneous tumor biopsies [7]. Single cell stem cells were very tough to 
extract from heterogeneous populations of tumour, however; recent innovative single-cell 
sequencing to profile the gene-expression landscapes of more than 20,000 cells in the motor 
cortex of brain [8], makes it possible for complex tumors to track the subclonal evolution 
through phylogenetic analysis [9].
Subclonal evolution of cancer as tackled by immunotherapy is recognized by the 2018 Nobel 
prize in Physiology or Medicine, awarded jointly to James P. Allison and Tasuku Honjo [10] 
for his discoveries of how the immune system recognizes tumor cells – they have created a 
change in thinking in subclonal treatment by immune-based therapies. Immunotherapies, 
which boost the body’s own immune system to eliminate cancerous cells, could be an 
alternative approach to target CSCs [11]. Targeting an interlinked network that connects 
pluripotency factors and key cell cycle genes of CSCs may improve efficacy [12]. Thus, 
Immunotherapy using autologous CD19 based modified T-cells (CAR-T cells) for cancer 
raises hope for cancer patients [13]. A highly competent and educated reservoir of immune 
cells may exist within the spleen, in which a specialized environment exists for splenic 
CD11b(+)Gr-1(int)Ly6C(hi) cells, mostly comprising proliferating CCR2(+)-inflammatory 
monocytes in the marginal zone of the spleen [14]. These cells, closely associated with 
memory CD8(+) T cells, cross-presenting tumor antigens can result in tipping the balance 
toward recognition or tolerance but these same cells may also be significantly depleted or 
completely abrogated during treatment cycles with chemotherapy, leading to lack of tumor-
specific immunity [15]. Ability to fight infection and tumor by these immune cells is 
abolished by chemotherapy due to the destruction of established memory achieved by 
previous antigen recognition. All these immune approaches need to target CSCs or TICs 
subclones, therefore; isolation of patient CSCs is essential for the determination of such 
targeting strategies [7]. We use HNSCC as an example to illustrate such an approach step-
by-step.
First, it is essential to define the Head and Neck Squamous Cell Cancer (HNSCC) stem cells 
by the biomarkers. The aldehyde dehydrogenase (ALDH) is a polymorphic enzyme 
responsible for the oxidation of aldehydes to carboxylic acids. ALDH can be used in the 
identification of CSCs [16] in HNSCC. It has been shown that stem cells express elevated 
levels of ALDH. Chemoresistant cancer cells express high levels of ALDHs, particularly in 
HNSCC. The ALDH family of enzymes detoxifies both exogenous and endogenous 
aldehydes. Since many chemotherapeutic agents, such as cisplatin, result in the generation of 
cytotoxic aldehydes and oxidative stress, we hypothesized that cells expressing elevated 
levels of ALDH may be more chemoresistant due to their increased detoxifying capacity and 
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that inhibitors of ALDH may sensitize them to these drugs. In another word, HNSCC-CSCs 
can be identified by high cell-surface expression of CD44 and high intracellular activity of 
ALDH, termed ALDHhighCD44high [17]. Microarray analysis of cisplatin-resistant 
ALDHhighCD44high cells indicates that their signaling pathways have significant 
implications for the pathobiology of cancer (e.g. TNFα, IFN, IL6/STAT, NF-κB, FGF2) 
[17]. The activation of ALDH3A1 by a small molecule activator (Alda-89) increased 
survival of ALDHhigh HNSCC cells treated with cisplatin while treatment with a novel 
small molecule ALDH inhibitor (Aldi-6) resulted in a marked decrease in cell viability, 
suggesting a promising strategy [18].
Second, HNSCC cells that are resistant to chemotherapy, lead to tumor recurrent or 
metastatic that has the poor prognosis with less than 1 year median survival and [17]. 
Autologous CSCs for the screening of personalized treatment (precision medicine) can be 
derived from HNSCC pateint specimens. Studies in our lab have revealed that both CSC and 
its related tumor microenvironment can be used for therapeutic detection before 
administration to patients. We think that tumor surveillance and response by these patient’s 
autologous CSC screening help determine how patient’s CSC react and evolve with 
therapeutics, i.e., co-evolution of CSCs with therapeutics. Reports from brain tumor stem 
cells in glioma patients [7] and in primitive neuroectodermal tumor [19,20] with single-cell 
transcriptome for relapse prognosis [21] and in situ hybridization [22] prompted us to realize 
that patient’s HNSCC CSCs (HNCSC) possess a capacity for tumor evolution of 
therapeutics as such development shows prognostic value for patients. With upregulation of 
vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) of highly 
angiogenic phenotypes, tumor endothelial cells (TECs) exhibit higher proliferative and 
migratory capacity, compared with those of normal endothelial cells (NECs). Such TECs 
show ALDHhigh cell populations by fluorescence-activated cell sorting (FACS) [23]. Sheng 
et al. [24] demonstrated that with decreased ALDH activity, the expression levels of 
stemness-associated markers, CD133+, octamer-binding transcription facto 4 (Oct4) and sex 
determining region Y box 2 also reduced. They also showed, “an increased number of mice 
developed tumors in the ALDHhigh group 16 weeks following the injection of 500 cells, 
whereas tumors appeared at eight weeks in the ALDHlow group”. The mice in the 
ALDHneg group exhibited less tumor formation under these conditions.” They conclude that 
“ALDHhigh cells had characteristics of self-renewal ability, in a relative resting stage; while 
the ALDHlow cells had characteristics of GCPCs with limited self-renewal ability, but were 
in a rapid proliferation stage” [24]. Thus, HNCSC cells can be identified with drugs 
sensitive to ALDH(high)+ cells and isolated with their resistance to fluorouracil (5-FU) in 
vitro and in vivo, while tumor endothelial cells (TEC) can be identified with high ALDH 
activity (ALDHhigh), along with upregulation of stem-related genes such as multidrug 
resistance 1, CD90, ALP, Oct-4, Platelet-derived growth factor (PDGF)-A [25].
Third, as well documented in glioblastomas [26], medulloblastoma [27], leukemia [28] and 
germ cell tumors [29]: all of these cancer types evolve with treatment (radiation and 
chemotherapy) surviving by coming up with new mutations in subclonal evolution, which 
can be defined by single-cell transcriptome technology (Figure 1). For example, “Although 
well-tolerated, the efficacy of bevacizumab was somewhat disappointing, possibly due to the 
high rate of secondary high-grade gliomas in the studied patient cohort and the late use of 
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bevacizumab in the course of the disease” [30]. Following analysis of tumor specimens, 
distinct molecular pathogenesis of secondary tumor arising after radiation therapy was 
determined by cancer genome-scale technology for genomic mutation signatures, 
particularly, discovered in secondary neoplasms after cranial or craniospinal radiation in 
high-grade astrocytomas that prognoses for poor clinical outcomes [31]. Surprisingly, this 
cohort had “a high frequency of TP53 mutations, CDK4 amplification or CDKN2A 
homozygous deletion and amplification or rearrangements involving receptor tyrosine kinase 
and Ras-Raf-MAP kinase pathway genes including PDGFRA, MET, BRAF and RRAS2,” 
but, “lacked alterations in IDH1, IDH2, H3F3A, HIST1H3B, HIST1H3C, TERT (including 
promoter region) and PTEN, which genetically define the major subtypes of diffuse gliomas 
in children and adults.” Such subclonal changes can be tracked down using single-cell RNA 
sequencing, as shown in 3321 single-cells from six primary H3K27M-glioma and matched 
models, for the discovery of “oncogenic and developmental programs in H3K27M-glioma at 
single-cell resolution and across genetic subclones.” This subclonal tracking surfaces a 
therapeutic window [32] on potential therapeutic targets.
To identify a therapeutic window [32] on potential therapeutic targets, we need to define 
spatiotemporal expression patterns of new biomarkers from HNSCC to significantly improve 
the efficacy of therapies. As such a new biomarker, known a molecular mechanism, AF4/
FMR2 family member 4 (AFF4), the core component of Super elongation complex (SEC), is 
upregulated dramatically in HNSCC, which is a potential target of therapies for patients with 
HNSCC [33]. Besides, Disulfiram (DS) has been reported as an inhibitor of ALDH and 
increasing studies showed it has anti-cancer effects in a copper (Cu)-dependent manner [34]. 
As “DS/Cu inhibited the expression of stem cell transcription factors NANOG and OCT4, 
and abolished the clonogenicity of multiple myeloma,” we postulate that DS may regulate 
HNSCC stem cells. Another line of evidence that “HNSCC contains cancer stem cells 
(CSCs) that have greater radioresistance and capacity to change replication dynamics in 
response to irradiation compared to non-clonogenic cells [35],” can help characterize the 
effects of radiotherapy on “CD44+/ALDH+” HNSCC stem cells derived from patients, 
providing screening for responsible patients, as “CD44+/ALDH+” HNSCC stem cells are of 
radioresistance. Hyaluronan (HA), an important glycosaminoglycan component of the 
extracellular matrix (ECM) and its major cell surface receptor, CD44, Nanog/Oct4/Sox2, 
have been suggested to be important cellular mediators influencing tumor progression and 
treatment resistance in head and neck cancer [36]. Personalized medicine-based approach 
can model the patterns of chemoresistance and tumor recurrence using ovarian cancer stem 
cell spheroids [37]. Gene set enrichment analysis and iPathway analysis identified signaling 
pathways with major implications to the pathobiology of cancer (e.g. TNFα, IFN, IL6/STAT, 
NF-κB) that are enriched in cisplatin-resistant ALDHhighCD44high cells when compared to 
control cells. Such pathway analysis establishes the relationship between CD44high/
CD133high/CD117high cancer stem cells phenotypes and Cetuximab and Paclitaxel treatment 
responses in head and neck cancer cell lines [38].
Fourth, a new concept of “living with cancer subclones” or “co-habit with cancer subclones” 
[39] sounds odd and against the decades-long dominant trend of “targeted molecular 
destruction of cancer,” however; its focus on modifying the tumor microenvironment [40] 
gains attention with clinically proven case reports. When the treatment benefits and the side 
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effects sound odd, can the patients risk their lives for such an intervention? That is 
particularly promising given the effect of epigenetics [41], immunotherapy [42] and 
microbiome [43] on cáncer; all lead to a wait-and-watch approach to disease, due to the fact 
that we can monitor the relapse pathway [44].
CONCLUSION
In Summary, to achieve above benefits for a patient, we need to isolate the patient’s CSCs 
(Which is the REAL CHALLENGE still!), and to determine the mechanism by which 
subclones of ALDHhighCD44high HNCSCs resist to drugs via single-cell transcriptome, as 
we show with breast cancer, with specified tissue-relevant tumor microenvironment [45]. 
Measuring survival of HNCSC CSC lines in presence of cisplatin (or other FDA approved 
drugs) in cellular models for cancer subclonal evolution [39] can help develop therapeutics 
to drive cancer cells to dormancy, which is a lifetime subclonal evolution process 
developmentally evolved with local environments to cancer. All the procedures are still 
ongoing and under way - They need long-term monitoring and confirmation if they indeed 
work.
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Sequential perturbations of cell-cycle-phase-specific genes derived from single-cell 
transcriptomes of patient tumors are applied to treatment. A: After organizing single-cell 
transcriptomes by similarity into a sequential order (center-clustering), expression levels of 
various cell-cycle-phase-specific genes were plotted to visualize the sequential perturbation 
of individual genes during the cell cycle, a virtual time series. Expression levels were scaled 
from 0 (undetectable) to 1 (maximum expression). Cell cycle phases were defined and 
colored. As expected, G0/G1-specific genes had higher expression levels in the G0/G1 phase 
and an S-specific gene was mainly expressed within the S phase. G2/M-specific genes had 
high expression levels in G2/M phase and early G0/G1 phase. The sequential expression 
order suggests that mRNAs of many G2/M-specific genes are not degraded until early in 
G0/G1 phase after cell division. B, C: Cancer subclones are defined by single-cell 
transcriptome-clustered cell cycle gene clustering, which is used to guide treatment. 
(Adopted from Li, S.C., et al. 2018 [2])
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